|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
18 Pt 1
|
|
pubmed:dateCreated |
2004-9-27
|
|
pubmed:abstractText |
Cytokine-induced modulation of innate immunity is being explored to enhance the activity of monoclonal antibodies. Severe combined immunodeficient (SCID) mice engrafted with peripheral blood leukocytes (PBLs) from Epstein Barr virus-seropositive donors develop human B-cell non-Hodgkin's lymphomas [B-NHLs (hu-PBL-SCID mouse model)]. We used this hu-PBL-SCID mouse model to study the synergism between interleukin (IL)-2 and rituximab. We also conducted a phase I trial of IL-2 and rituximab in relapsed B-NHL to study whether expansion of natural killer (NK) cells and enhanced cellular cytotoxicity could be safely accomplished in vivo.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:BaiocchiRobert ARA,
pubmed-author:BanksAmy LAL,
pubmed-author:ByrdJohn CJC,
pubmed-author:CaligiuriMichael AMA,
pubmed-author:CarrodeguasLesterL,
pubmed-author:ChenLeiL,
pubmed-author:DavisThomasT,
pubmed-author:EisenbeisCharles FCF,
pubmed-author:FischerBethB,
pubmed-author:GraingerAndrewA,
pubmed-author:GreverMichael RMR,
pubmed-author:KelbickNicoleN,
pubmed-author:PorcuPierluigiP,
pubmed-author:RoychowdhurySameekS,
pubmed-author:StephensJulieJ,
pubmed-author:YoungDonnD
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
10
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
6101-10
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:15447996-Adult,
pubmed-meshheading:15447996-Aged,
pubmed-meshheading:15447996-Aged, 80 and over,
pubmed-meshheading:15447996-Animals,
pubmed-meshheading:15447996-Antibodies, Monoclonal,
pubmed-meshheading:15447996-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:15447996-Antineoplastic Agents,
pubmed-meshheading:15447996-Combined Modality Therapy,
pubmed-meshheading:15447996-Female,
pubmed-meshheading:15447996-Humans,
pubmed-meshheading:15447996-Immunotherapy,
pubmed-meshheading:15447996-Interleukin-2,
pubmed-meshheading:15447996-Killer Cells, Natural,
pubmed-meshheading:15447996-Leukocytes,
pubmed-meshheading:15447996-Leukocytes, Mononuclear,
pubmed-meshheading:15447996-Lymphoma, B-Cell,
pubmed-meshheading:15447996-Lymphoma, Non-Hodgkin,
pubmed-meshheading:15447996-Male,
pubmed-meshheading:15447996-Mice,
pubmed-meshheading:15447996-Mice, SCID,
pubmed-meshheading:15447996-Middle Aged,
pubmed-meshheading:15447996-Time Factors,
pubmed-meshheading:15447996-Treatment Outcome
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study.
|
|
pubmed:affiliation |
Division of Hematology/Oncology, Comprehensive Cancer Center, and Center for Biostatistics, The Ohio State University, Columbus, Ohio 43210, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
